Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $\begin{array}{l} Introduced\ 01/07/96\ \ Origin:\ Appendix\ 5\ \ Amended\ 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13 \end{array}$ 

Name of entity			
Atcor Medical Holdings Lir	nited		
ABN			
81 113 252 234			

We (the entity) give ASX the following information.

#### Part 1 - All issues

 $You \ must \ complete \ the \ relevant \ sections \ (attach \ sheets \ if \ there \ is \ not \ enough \ space).$ 

- †Class of \*securities issued or to be issued or to
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued

  41,500,000 Ordinary Shares
- Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

Fully Paid Ordinary Shares

<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted +securities? If the additional \*securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend. distribution interest payment 5 Issue price or consideration 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) "Placement 1". Is the entity an \*eligible entity 6a No that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the \*securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder N/A resolution under rule 7.1A was passed Number of \*securities issued 6с N/A without security holder approval under rule 7.1 Number of \*securities issued 6d N/A with security holder approval

they rank equally with all other Yes. Ordinary Shares.

\$0.02 per Ordinary Share

To provide funds as a first stage capital raising to fund the new business strategy of the Company and to provide additional working capital previously announced as

under rule 7.1A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued under an exception in rule 7.2	N/A
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
-1		[
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and	LR7.1: 8,842,979
	rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	LR71A: N/A
7	<sup>+</sup> Issue dates	01 May 2018
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	
	Cross reference: item 33 of Appendix 3B.	

<sup>+</sup> See chapter 19 for defined terms.

8	Number	and	+class	of	all
	+securities	s qu	oted	on	ASX
	(including	the	+secu	rities	in
	section 2 i	f appli	cable)		

Number	+Class
378,728,193	Fully paid ordinary shares (including 56,204,699 Shares To be issued under Entitlements Issue)
28,102,350	Listed Options (28,102,350 Options To be issued under Entitlements Issue)

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

	Number	<sup>+</sup> Class
	15,053,333	Unlisted options
l		

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

The Company does not have a dividend policy

#### Part 2 - Pro rata issue

11 Is security holder approval required?

N/A

12 Is the issue renounceable or non-renounceable?

N/A

Ratio in which the \*securities will be offered

N/A

14 \*Class of \*securities to which the offer relates

N/A

15 <sup>+</sup>Record date to determine entitlements

N/A

16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

N/A

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

29	Date applio	rights trading will end (if cable)	N/A
30		do security holders sell their ements in full through a r?	N/A
31			N/A
32	of the	do security holders dispose eir entitlements (except by nrough a broker)?	N/A
33	<sup>+</sup> Issue	e date	N/A
		Quotation of securit omplete this section if you are app	
34	Type (tick o	of <sup>+</sup> securities one)	
(a)		<sup>+</sup> Securities described in Part	1
(b)	All other +securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entiti	es tha	at have ticked box 34(a)	
Addit	ional :	securities forming a new	class of securities
Tick to docume		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36	If the *securities are *equity securities, a distribution schedule of the additiona *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000		

Appendix 3B Page 6 04/03/2013

 $<sup>\</sup>boldsymbol{+}$  See chapter 19 for defined terms.

	100,001 and over		
37	A copy of any trust deed for the	he additional <sup>+</sup> securities	
Entiti	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought	N/A	
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of	N/A	
	another +security, clearly identify that other +security)		
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	Number N/A	+Class

**Quotation agreement** 

<sup>+</sup> See chapter 19 for defined terms.

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

(Director/Company secretary)

Date: 01 May 2018

Print name:

Jarrod T White

Appendix 3B Page 8 04/03/2013

== == == == ==

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B - Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exc	ceeding 15% of capital
Step 1: Calculate "A", the base figures capacity is calculated	ure from which the placement
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	233,630,539
Add the following:	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2	47,392,955 (25/05/17) 56,204,699 (entitlements issue)
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval	
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	NIL
"A"	337,228,193

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	50,584,229
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	
• Under an exception in rule 7.2	241,250
Under rule 7.1A	41,500,000
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	41,741,250
Step 4: Subtract "C" from ["A" x "l placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	50,584,229
Note: number must be same as shown in Step 2	
Subtract "C"	(41,741,250)
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	8,842,979
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	N/A	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	N/A	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<ul> <li>Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	N/A	
"E"	N/A	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	N/A	
Note: number must be same as shown in Step 2		
Subtract "E"	N/A	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	N/A	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.